Cidara Therapeutics, Inc. (CDTX) has divested its antifungal drug, rezafungin, to Mundipharma, enabling an estimated $128 million in cost savings. This strategic move allows Cidara to concentrate on advancing its Cloudbreak DFC pipeline, including the development of its lead oncology candidate, CBO421. The divestiture includes transferring future royalties, milestones, and other assets related to rezafungin to Mundipharma, which already held commercial rights outside the U.S. and Japan. This decision follows Cidara's successful development and approval of rezafungin in the US, EU, and UK for life-threatening fungal infections.